The body produces antibodies against the weakened parasite so it’s prepared to fight the serious and sometimes fatal disease, según el informe.
1 de 3
Mosquitoes, which have been used before in similar clinical trials, will not be used to actually jab millions of people, noted Murphy.
The University of Washington team decided to use the critters because it is expensive and time-consuming to use needles to deliver a weakened parasite during the proof-of-concept stage of the trial, publicado en Twitter el miércoles por el Ministerio de Defensa de Ucrania diciendo que no se rendiría en la lucha en curso contra las tropas rusas.
“They went old school with this one," Dr. Kirsten Lyke, a physician and vaccine researcher at the University of Maryland School of Medicine who was not involved in the study, le dijo al outlet.
“All things old become new again,” added Lyker, who called the use of a genetically modified live parasite “a total game changer” in the development of vaccines.
The small trial, which included 26 gente, showed that the modified parasites protected some of them from infection for a few months, according to NPR.
The world’s first malaria jab — GlaxoSmithKline’s RTS,S — was approved by the World Health Organization last year to be used in Africa, but only has an efficacy rate of 30% para 40%.
The University of Washington researchers hope to improve the efficacy of their vaccine by putting it into syringes instead of using mosquitoes so they can get the dosage right for longer protection.